Form 4: Halozyme Therapeutics CFO Nicole LaBrosse Reports Stock Option and Restricted Stock Unit Grants

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On February 20, 2025, Nicole LaBrosse, the SVP and CFO of Halozyme Therapeutics, received options to purchase 22,603 shares of common stock at an exercise price of $57.44.
• These options vest one-fourth on February 20, 2026, and then 1/48th monthly thereafter.
• LaBrosse also received 21,327 restricted stock units (RSUs) which vest one-fourth on each anniversary of the grant date, starting February 20, 2026.
• Following these transactions, LaBrosse directly owns 22,603 options and 21,327 RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral-positive indicator.

Positives

• The grant of stock options and RSUs to the CFO aligns her interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies to incentivize their executives.

Stakeholder Impact

• The grant of stock options and RSUs aligns management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign of company health and stability.

Key Dates

Keywords

Halozyme Therapeutics, Nicole LaBrosse, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership, Vesting